Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Science 37 Holdings, Inc. specializes in decentralized clinical trials, leveraging technology to streamline patient recruitment and data collection across multiple geographies, primarily in North America and Europe. Its competitive position is strengthened by a proprietary platform that integrates telemedicine and mobile health technologies, enabling faster and more efficient trial processes.
Science 37 generates revenue primarily through providing decentralized clinical trial services, which include patient recruitment, data management, and regulatory compliance. The company benefits from a unique competitive advantage through its integrated technology platform, which reduces trial timelines and costs, enhancing client value and retention.
Regulatory approvals for new clinical trial methodologies
Partnership announcements with pharmaceutical companies
Changes in healthcare regulations affecting clinical trials
Technological advancements in telemedicine and data analytics
Technological disruption in clinical trial methodologies
Regulatory changes impacting trial processes
Emergence of new competitors offering similar decentralized trial services
Potential consolidation in the healthcare information services sector
Negative operating cash flow impacting liquidity
High valuation multiples relative to revenue growth
moderate - As a healthcare service provider, demand for clinical trials may be somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP fluctuations.
Interest rates impact the cost of capital for Science 37, potentially affecting its ability to invest in technology and expand operations. Higher rates could also dampen spending by pharmaceutical clients.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors are likely attracted to the potential for rapid revenue growth in a niche market.
high - The stock has shown significant price fluctuations, reflecting market sentiment and operational challenges.
